7 Facts About PEA (Palmitoylethanolamide) and Its Emerging Role in Menopause Pain and Neuroinflammation
The pain that no one can quite explain — the burning skin, the aching joints that move around, the feeling that your nervous system is just turned up too loud — that was one of the hardest parts for Rose to make sense of. Finding out there's an actual biological mechanism behind it, and that the body even makes its own compound to try to dampen it down, made the whole experience feel a little less like falling apart and a little more like chemistry.
Learn more about Rose →PEA Is Something the Body Already Makes — It's Not Foreign
Palmitoylethanolamide is an endogenous lipid mediator, meaning the human body synthesises it on demand in response to tissue damage or inflammation. It belongs to the same fatty acid amide family as the endocannabinoid system's own molecules, though it works through its own distinct receptors — primarily PPAR-α and GPR55. Because it is body-identical, it is generally well tolerated and does not carry the receptor-downregulation risks associated with many synthetic anti-inflammatory drugs.
Oestrogen Loss Directly Increases Neuroinflammation — Which Is Where PEA Comes In
Oestrogen has well-documented anti-inflammatory effects on the central nervous system, including suppression of microglial activation — the brain's resident immune cells. When oestrogen declines during perimenopause, microglial cells become more reactive, contributing to a state of low-grade neuroinflammation that researchers link to brain fog, mood shifts, pain hypersensitivity, and fatigue. PEA's primary mechanism of action is the downregulation of mast cell and microglial activation, making it physiologically relevant to exactly this hormonal transition.
Clinical Evidence for Neuropathic Pain Is the Strongest Signal So Far
Multiple randomised controlled trials and a 2012 meta-analysis by Gabrielsson and colleagues — later supported by an updated pooled analysis of over 1,600 patients — found PEA supplementation significantly reduced neuropathic and chronic pain scores compared to placebo or standard care. The conditions studied include sciatic pain, diabetic neuropathy, and chemotherapy-induced peripheral neuropathy, all of which share a nerve-inflammation pathway common in menopausal pain presentations. Effect sizes were modest to moderate, but consistency across independent trials is meaningful.
Fibromyalgia and Central Sensitisation Are a Plausible Target
Fibromyalgia — characterised by widespread musculoskeletal pain and sensory hypersensitivity — is significantly more prevalent in women during and after perimenopause, a pattern researchers attribute in part to oestrogen-dependent modulation of pain thresholds. PEA has been investigated in small clinical trials for fibromyalgia specifically, with one Italian RCT reporting reduced pain and fatigue scores after 12 weeks of supplementation. The working hypothesis is that by dampening mast cell degranulation and spinal cord sensitisation, PEA may raise the pain threshold that drops when oestrogen does.
Mast Cell Activation Syndrome and Perimenopause Have a Documented Overlap
Mast cells — immune cells distributed throughout connective tissue, the gut, skin, and nervous system — are directly regulated by oestrogen, and mast cell activation syndrome (MCAS) frequently worsens or first appears during perimenopause. PEA was originally investigated in the 1990s specifically for its mast-cell-stabilising properties, and that mechanism remains one of its most well-characterised actions in the literature. For women whose menopause transition includes sudden-onset food sensitivities, flushing, skin reactivity, or unexplained gastrointestinal symptoms, the PEA-mast cell connection is worth understanding.
Particle Size Matters — and Not All PEA Supplements Are Equivalent
One consistent finding across PEA research is that bioavailability is highly dependent on particle size, since PEA is poorly soluble in water and absorbs inconsistently from the gut in its standard crystalline form. Micronised and ultra-micronised (um-PEA) formulations have been shown in pharmacokinetic studies to achieve significantly higher plasma concentrations than non-micronised versions at the same dose. This is not a brand recommendation — it is a formulation science point, and it means that checking whether a product specifies micronisation is a genuinely relevant question when evaluating options.
PEA Is Not a Hormone Replacement — But It May Work Alongside HRT
PEA operates through lipid-signalling and immune pathways entirely separate from the oestrogen receptor system, which means it addresses downstream inflammation rather than the upstream hormonal deficit driving it. In clinical settings it has been used as an adjunct to standard pain management, not as a standalone replacement for any therapy, and there is no evidence that it restores the systemic benefits of oestrogen on bone, cardiovascular tissue, or vaginal health. For women who are not candidates for HRT, or who are managing residual pain symptoms while on HRT, PEA represents a low-risk addition to consider discussing with a knowledgeable clinician.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.